Alaunos Therapeutics Sees 12.9% Weight Loss in Obese Mice, Plans Financing
ALN1003 achieved 12.9% body weight reduction by day 13 in diet-induced obese mice, with liver weight cut by up to 43% and sustained through day 48. Long-term dosing produced significant drops in ALT, AST, ALP and blood sugar, prompting plans for extra financing for preclinical and CMC work.
1. Preclinical Weight-Loss Results
ALN1003 delivered a mean 12.9% reduction in body weight by day 13 in diet-induced obese mice, maintaining that deficit versus control subjects through day 48, demonstrating robust proof-of-concept for obesity treatment.
2. Liver and Metabolic Biomarkers
Treated mice experienced up to a 43% reduction in liver weight, along with highly significant decreases in ALT (p<0.0001), AST and ALP, a trend toward lower bilirubin and marked reductions in blood sugar and cholesterol levels.
3. Development Roadmap and Financing
The company plans to raise additional capital to fund ongoing CMC optimisation, blinded liver fat and MASLD mechanism studies, initial and scale-up manufacturing runs, computational chemistry for ALN1003 variants and large animal pharmacokinetic work ahead of IND-enabling activities.